5 Top Performing European Stocks So Far in 2023

4. Celyad Oncology SA (NASDAQ:CYAD)

YTD Gains as of March 23: 77%

Belgium-based Celyad Oncology SA (NASDAQ:CYAD) uses chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Celyad Oncology SA (NASDAQ:CYAD) ranks 4th in our list of the top performing European stocks so far in 2023. Celyad Oncology SA (NASDAQ:CYAD) however fell a whopping 30% earlier this month after the company said it will recognize a non-cash impairment of its goodwill and intangible oncology assets. Celyad Oncology SA (NASDAQ:CYAD) also said its board plans to submit a vote for its business plan, including a proposal to continue the company’s activities at the shareholders’ meeting.

Michael Novogratz’s Fortress Investment Group owns a $3.2 million stake in Celyad Oncology SA (NASDAQ:CYAD) as of the end of the fourth quarter of 2022.